PASS of Paediatric Patients Initiating Selumetinib

Trial Identifier:	D1346R00004
Sponsor:	AstraZeneca
NCTID::	NCT05388370
Start Date:	May 2022
Primary Completion Date:	May 2027
Study Completion Date:	May 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
France	Angers, France
Germany	Duisburg, Germany
Germany	Tübingen, Germany
Portugal	Lisbon, Portugal

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.